Literature DB >> 19885684

Pharmacokinetics of tacrolimus in stable paediatric renal transplant recipients.

Tania Claeys1, Maria Van Dyck, Rita Van Damme-Lombaerts.   

Abstract

Because tacrolimus (Tac) has a narrow therapeutic index and highly inter- and intra-individual variable pharmacokinetic (PK) characteristics, monitoring of drug exposure is recommended, but limited data are available on the kinetics of Tac in paediatric renal transplant recipients, especially of limited sampling strategies. To investigate the correlation between Tac trough level (TL) and the 0-12 h area under the curve (AUC), and the value of abbreviated AUC monitoring, we evaluated 12 h PK profiles in 27 children at least 1 year after transplantation. There was a significant discrepancy between Tac TLs and 0-12 h AUC (r = 0.60). Every time point, different from C(0), gave a better prediction for the drug exposure, with C(4) and C(6) as best predictors (r = 0.93 and r = 0.92, respectively). The 0-12 h AUC was estimated with great precision by the use of a two- or three-point sampling strategy, and the latter is more time-point independent. In paediatric renal transplant recipients on Tac maintenance therapy, whose condition is stable, Tac TL is not a reliable tool for the estimation of drug exposure. Abbreviated monitoring, especially at three points in time, give reliable predictions of the complete 0-12 h AUC. We suggest a 0-12 h AUC of around 150 ng x h/ml for stable paediatric renal transplant recipients 1 year after transplantation and around 100 ng x h/ml in the following years. Target AUC values should be further established for paediatric transplant recipients according to the time after transplantation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19885684     DOI: 10.1007/s00467-009-1331-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  23 in total

1.  Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.

Authors:  Guido Filler; Nicholas J A Webb; David V Milford; Alan R Watson; Jutta Gellermann; Gunnar Tyden; Ryszard Grenda; Karel Vondrak; David Hughes; Gisela Offner; Martin Griebel; Inge B Brekke; Mary McGraw; Egon Balzar; Styrbjörn Friman; Richard Trompeter
Journal:  Pediatr Transplant       Date:  2005-08

2.  Optimal combination of immunosuppressive agents for renal transplantation: first report of a multicentre, randomised trial comparing cyclosporine+prednisolone with cyclosporine+azathioprine and with triple therapy in cadaver renal transplantation. The Australian Collaborative Trials Committee.

Authors:  I R Hardie; D J Tiller; J F Mahony; P J Miach; N M Thomson; G N Thatcher; R J Rigby; B L Menzies
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

3.  Kidney transplantation under FK 506.

Authors:  T E Starzl; J Fung; M Jordan; R Shapiro; A Tzakis; J McCauley; J Johnston; Y Iwaki; A Jain; M Alessiani
Journal:  JAMA       Date:  1990-07-04       Impact factor: 56.272

4.  Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants.

Authors:  G Filler; R Grygas; I Mai; H J Stolpe; C Greiner; S Bauer; J H Ehrich
Journal:  Nephrol Dial Transplant       Date:  1997-08       Impact factor: 5.992

5.  Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids.

Authors:  Dennis A Hesselink; Hien Ngyuen; Marike Wabbijn; Peter J H Smak Gregoor; Ewout W Steyerberg; Iza C van Riemsdijk; Willem Weimar; Teun van Gelder
Journal:  Br J Clin Pharmacol       Date:  2003-09       Impact factor: 4.335

6.  C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients.

Authors:  Kaj Jørgensen; Johan Povlsen; Søren Madsen; Melvin Madsen; Hans Hansen; Asger Pedersen; Else-Marie Heinsvig; Jørgen Poulsen
Journal:  Nephrol Dial Transplant       Date:  2002-08       Impact factor: 5.992

7.  CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.

Authors:  D R J Kuypers; H de Jonge; M Naesens; E Lerut; K Verbeke; Y Vanrenterghem
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

8.  Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation.

Authors:  Martin N Lee; Lavjay Butani
Journal:  Pediatr Transplant       Date:  2007-06

9.  Population pharmacokinetics of tacrolimus in adult kidney transplant recipients.

Authors:  Christine E Staatz; Charlene Willis; Paul J Taylor; Susan E Tett
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

10.  Use of cyclosporine in pediatric renal transplant recipients.

Authors:  S B Conley; S M Flechner; G Rose; C T Van Buren; E Brewer; B D Kahan
Journal:  J Pediatr       Date:  1985-01       Impact factor: 4.406

View more
  5 in total

Review 1.  Therapeutic drug monitoring in pediatric renal transplantation.

Authors:  Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2014-04-25       Impact factor: 3.714

2.  The Effect of Weight and CYP3A5 Genotype on the Population Pharmacokinetics of Tacrolimus in Stable Paediatric Renal Transplant Recipients.

Authors:  Agnieszka A Prytuła; Karlien Cransberg; Antonia H M Bouts; Ron H N van Schaik; Huib de Jong; Saskia N de Wildt; Ron A A Mathôt
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

3.  Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in paediatric liver transplant recipients.

Authors:  Nastya Kassir; Line Labbé; Jean-Romain Delaloye; Mohamad-Samer Mouksassi; Anne-Laure Lapeyraque; Fernando Alvarez; Michel Lallier; Mona Beaunoyer; Yves Théorêt; Catherine Litalien
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

Review 4.  Clinical aspects of tacrolimus use in paediatric renal transplant recipients.

Authors:  Agnieszka Prytuła; Teun van Gelder
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

5.  Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study.

Authors:  Anne-Laure Lapeyraque; Nastya Kassir; Yves Théorêt; Maja Krajinovic; Marie-José Clermont; Catherine Litalien; Véronique Phan
Journal:  Pediatr Nephrol       Date:  2014-01-17       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.